Catalyst
Slingshot members are tracking this event:
Final Decision Expected from European Commission in ~60 Days on Novarits' (NVS) Arzerra in Adult Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 12, 2016
Occurred Source:
https://globenewswire.com/news-release/2016/12/12/896995/0/en/European-Commission-Grants-Marketing-Authorization-for-Arzerra-ofatumumab-in-combination-with-Fludarabine-and-Cyclophosphamide-in-Relapsed-CLL.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Final Decision, European Commission, Chmp, Arzerra, Chronic Lymphocytic Leukemia, Cll
